Inspired by the urgent needs of children with cancer, Day One creatively and intentionally develops new oncology medicines that change outcomes for patients of all ages. Historically, new cancer treatments are developed almost exclusively for adults, which limits progress and access for children. Day One prioritizes products that can benefit children and adults with cancer and accelerates the path to FDA approval by including people of all ages in clinical studies from the start. Day One’s lead product is DAY101, a clinical-stage potent selective oral, once-a-week, small molecule type II inhibitor of RAF, an oncogenic driver in a range of cancers including pediatric glioma and adult solid tumors. Day One went public in June 2021 (NASDAQ: DAWN).
|Headquarters||South San Francisco, CA|
|Day One Bio|